KRAS and colorectal carcinoma: The mutation status of the KRAS gene has been observed to affect the response of CRC toward cetuximab treatment, cetuximab a monoclonal antibody that binds to the extracellular region of EGFR, is effective on KRAS wild type metastatic CRC [9,10,11].